GC Pharma [Green Cross Corporation] (KRX: 006280) is a headquartered in Yongin, South Korea. GC Pharma specializes in the development and commercialization of vaccines, protein therapies, and therapeutic antibodies for use in the fields of oncology and infectious disease. As part of GC Pharma's global strategies, there are three operations based in the overseas as of 2016.
| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:label
| - GC Pharma (de)
- Green Cross (South Korean company) (en)
- GC녹십자 (ko)
|
| rdfs:comment
| - ( 다른 뜻에 대해서는 그린 크로스 문서를 참고하십시오.) GC녹십자는 대한민국의 코스피에 등록되어 있는 의약품 제조기업으로 혈액분획제제와 백신제제에 중점을 두고 있다. (ko)
- GC Pharma (Green Cross Corporation) ist ein 1967 gegründetes biopharmazeutisches Unternehmen mit Hauptsitz in Yongin, Südkorea. GC Pharma ist auf die Entwicklung und Vermarktung von Impfstoffen, Proteintherapien und therapeutischen Antikörpern für die Onkologie und Infektionskrankheiten spezialisiert. Das Unternehmen wurde am 5. Oktober 1967 als „Sudo Microorganism Medical Supplies Co.“ gegründet und 1971 in „Green Cross“ umbenannt. Aktueller President ist Eun Chul Huh (Vorgänger: Huh Young-sup).Es wird unter der Kennung „KRX: 006280“ am Korea Exchange gehandelt. (de)
- GC Pharma [Green Cross Corporation] (KRX: 006280) is a headquartered in Yongin, South Korea. GC Pharma specializes in the development and commercialization of vaccines, protein therapies, and therapeutic antibodies for use in the fields of oncology and infectious disease. As part of GC Pharma's global strategies, there are three operations based in the overseas as of 2016. (en)
|
| foaf:name
| - GC Pharma(Green Cross Corporation) (en)
|
| name
| |
| foaf:depiction
| |
| location
| |
| dcterms:subject
| |
| Wikipage page ID
| |
| Wikipage revision ID
| |
| Link from a Wikipage to another Wikipage
| |
| sameAs
| |
| dbp:wikiPageUsesTemplate
| |
| thumbnail
| |
| foundation
| |
| homepage
| |
| key people
| |
| location
| |
| logo
| |
| services
| - Manufacturing and sales of biotheapeutics. (en)
|
| has abstract
| - GC Pharma (Green Cross Corporation) ist ein 1967 gegründetes biopharmazeutisches Unternehmen mit Hauptsitz in Yongin, Südkorea. GC Pharma ist auf die Entwicklung und Vermarktung von Impfstoffen, Proteintherapien und therapeutischen Antikörpern für die Onkologie und Infektionskrankheiten spezialisiert. Das Unternehmen wurde am 5. Oktober 1967 als „Sudo Microorganism Medical Supplies Co.“ gegründet und 1971 in „Green Cross“ umbenannt. Aktueller President ist Eun Chul Huh (Vorgänger: Huh Young-sup).Es wird unter der Kennung „KRX: 006280“ am Korea Exchange gehandelt. GC Pharma ist der größte Hersteller von Plasmaproteinprodukten in Asien. Im Dezember 2019 kooperierte GC Pharma mit dem estnischen Fitness-Blockchainunternehmen im Kampf gegen Fettleibigkeit. (de)
- GC Pharma [Green Cross Corporation] (KRX: 006280) is a headquartered in Yongin, South Korea. GC Pharma specializes in the development and commercialization of vaccines, protein therapies, and therapeutic antibodies for use in the fields of oncology and infectious disease. GC Pharma was established as "Sudo Microorganism Medical Supplies Co." in 1967, and changed the name to "Green Cross" in 1971. The company is engaged in research, development, manufacturing and sales of biotherapeutics, including plasma proteins, recombinant antibodies, and vaccines. Green Cross developed "Hepavax B", the world's third hepatitis B vaccine, in 1983, the world's first vaccine “Hantavax” against epidemic hemorrhagic fever in 1988, the world's second varicella vaccine in 1995, "Greengene", the world's 4th recombinant antihemophilic drug, and the world's second treatment of Hunter syndrome “Hunterase” in 2012. As part of GC Pharma's global strategies, there are three operations based in the overseas as of 2016.
* GC China was established in Anhui Province, China and, has produced plasma derivative products. GC China has established a pharmaceutical wholesaler in 2012.
* GCAM was established in December 2009 to secure plasma supply and enter into the US market. The company, currently runs a total of 8 plasma centers in the US, and collects 400,000 liters of plasma a year that meets FDA standards for facilities and quality and supplies it to Green Cross.
* GCBT is a Montreal-based biopharmaceutical company that was established in 2014 and is Green Cross’ business expansion into the North American and European markets. Building a state-of-the-art manufacturing facility for plasma proteins, GCBT will become the only intravenous immunoglobulin and albumin producer in Canada. It will also serve as a North American hub for the distribution of a variety of therapeutic products from the Green Cross family.
* MOGAM Institute was established in 1984 by Dr. Young-sup Huh who was the first CEO and chairman of GC Pharma (Green Cross Corporation). In 1970, he dedicated his life to create a sustainable biopharmaceutical industry in South Korea for the benefit of Koreans. Since then, his work led to the development of the world's third Hepatitis B vaccine. In 1984, Dr. Huh founded the MOGAM Institute using all of the profit generated from Green Cross Pharmaceuticals. Since its inception, MOGAM has made significant contributions to Korea’s biomedical industry by successfully producing vaccines, diagnostic kits, and important recombinant proteins. (en)
- ( 다른 뜻에 대해서는 그린 크로스 문서를 참고하십시오.) GC녹십자는 대한민국의 코스피에 등록되어 있는 의약품 제조기업으로 혈액분획제제와 백신제제에 중점을 두고 있다. (ko)
|
| prov:wasDerivedFrom
| |
| page length (characters) of wiki page
| |
| founding date
| |
| founding year
| |
| key person
| |
| foaf:isPrimaryTopicOf
| |
| is Link from a Wikipage to another Wikipage
of | |
| is Wikipage redirect
of | |
| is foaf:primaryTopic
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)
